The nursing role in the delivery of genetic services

Fibison, Wendy J.

doi:10.1080/07399338309510806

Cited by 14 publications

(23 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, nonsteroidal antiinflammatory medications for CF therapy are cur- rently being evaluated. Most of these treatments involve some degree of controversy as to efficacy and long-term safety (11,25,64).…”

Section: Lung Therapymentioning

confidence: 99%

“…In some patients, for example, currently available mucolytic aerosols induce cough, cause bronchospasm, and promote inflammation; bronchodilators, while often providing immediate relief of symptoms, might not be effective in long-term use and could even prove harmfud. Short-term use of corticosteroids in adults can cause detrimental effects such as immune system suppression, hyperglycemia, and glycosuriarequiring their use be evaluated on a patient-bypatient basis (25).…”

Section: Cystic Fibrosis and Dna Tests: Implications Of Carrier Scrmentioning

confidence: 99%

“…ASHG's leadership, based on its own analysis and not a poll of the membership, took the position that routine CF carrier screening is "NOT yet the standard of care" (25). The Committee on Obstetrics: Maternal and Fetal Medicine of the American College of Obstetricians and Gynecologists endorsed the ASHG position statement soon thereafter (44), and the AMA has also issued a similar position statement on CF carrier screening (49).…”

Section: Box 5-e-professional Societies and Standards Of Carementioning

confidence: 99%

“…Because genetic diseases sometimes cluster in ethnic or racial groups, will the potential for discrirnination and stigmatization be compounded (27,38)? Public misinformation, for example, can lead to a ''courtesy stigma' applied to those afffiated only by common ancestry to the stigmatized individuals (25,38).…”

Section: Stigmatization and Carrier Statusmentioning

confidence: 99%

“…While some relationship exists between a characteristic's visibility and the amount of stigma it arouses (29,57), nonvisible characteristics (e.g., carrier status) are also stigmatized (25). Individuals who reveal hidden differences often encounter hostility, aversion, or discomfort (25).…”

Section: Stigmatization and Carrier Statusmentioning

confidence: 99%

See 4 more Smart Citations

Cystic Fibrosis and DNA Tests—The Implications of Carrier Screening

Nishimi¹

1993

JAMA

View full text Add to dashboard Cite

Nearly 10 years ago, the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research speculated about the potential ethical, legal, and social consequences that might occur if a test were available to identify carriers for cystic fibrosis (CF) l , the most common, life-shortening, recessive genetic disease in American Caucasians. Time and technology have moved forward. The mysteries of biological inheritance-first explored by Austrian monk Gregor Mendel over a century ago-are yielding to modern science. A CF carrier test is no longer a prospect; it is now reality. The test's existence raises broad societal questions about the use of genetic information. And beyond CF tests, expectations of scores of additional genetic tests loom on the horizon as scientists in the United States and abroad pursue an ambitious mission to map and sequence the entire human genetic blueprint, or genome.Ongoing interest in the Human Genome Project, as well as concern about the potential magnitude and effects of routine CF carrier screening, led the House Committee on Science, Space, and Technology and the House Committee on Energy and Commerce to request an evaluation of the scientific, clinical, legal, economic, and social considerations of widespread carrier screening for CF. The study was also endorsed by Representative David R. Obey. Cystic Fibrosis and DNA Tests: Implications of Carrier Screening presents a range of options for action by the U.S. Congress in six broad policy areas:q genetics education and the public, q gentics training and education of health care professionals, q discrumination, . clinical laboratory and medical device regulation, q instrumentation to automate DNA diagnostics, and q integration of DNA assays into routine clinical practice.OTA prepared this report with the assistance of a panel of advisors and reviewers selected for their expertise and diverse points of view. Additionally, hundreds of individuals cooperated with OTA staff through interviews or by providing written material. These authorities were drawn from academia, industry, and professional societies, as well as Federal and State agencies. OTA gratefully acknowledges the contribution of each of these individuals. As with all OTA reports, however, responsibility for the content is OTA's alone.In publishing this report, OTA concludes that the value of the CF carrier test is the information it provides. No one can estimate in common terms what it means to an individual to possess information about his or her genetic status, especially when the value concerns reproductive decisionmaking. As our knowledge of the human genome increases, what we do with information such as CF carrier status will depend on the perceptions and beliefs of all Americans. We believe that public understanding of this new knowledge and its implications is necessary for its wise and thoughtful application.

show abstract

Section: Lung Therapymentioning

confidence: 99%

Section: Cystic Fibrosis and Dna Tests: Implications Of Carrier Scrmentioning

confidence: 99%

Section: Box 5-e-professional Societies and Standards Of Carementioning

confidence: 99%

Section: Stigmatization and Carrier Statusmentioning

confidence: 99%

Section: Stigmatization and Carrier Statusmentioning

confidence: 99%

See 3 more Smart Citations

Cystic Fibrosis and DNA Tests—The Implications of Carrier Screening

Nishimi¹

1993

JAMA

View full text Add to dashboard Cite

show abstract

Nursing and genetic health care

Lea

Williams

Tinley

1994

Journal of Genetic Counseling

View full text Add to dashboard Cite

Advances in DNA technology are leading to major developments in nursing practice in clinical genetics, including the creation of new roles for nurses who care for people with genetic conditions. Application of genetic information and testing is moving genetics into the mainstream of health care. Therefore, it is anticipated that nurses in all areas of practice will become involved in the provision of information about genetic testing and assisting individuals and families in decision making and adjustment to new genetic information. This article provides an overview of the profession of nursing which may be useful to genetic counselors in the development of collaborative relationships between the two professions.

show abstract

Wilms tumor: A paradigm, a parallel, and a puzzle

Ruccione

1992

Seminars in Oncology Nursing

View full text Add to dashboard Cite

The nursing role in the delivery of genetic services

Cited by 14 publications

References 36 publications

Cystic Fibrosis and DNA Tests—The Implications of Carrier Screening

Cystic Fibrosis and DNA Tests—The Implications of Carrier Screening

Nursing and genetic health care

Wilms tumor: A paradigm, a parallel, and a puzzle

Contact Info

Product

Resources

About